Drug guidance
Vonoprazan for treating Helicobacter pylori infection
Condition
Gastrointestinal tract
Infections
1 April 2020
Published on 01 Apr 2020
Last Updated on 01 Apr 2020
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended listing vonoprazan on the Medication Assistance Fund (MAF) for treating Helicobacter pylori infection due to low clinical need, uncertain clinical effectiveness and unfavourable cost-effectiveness compared to alternate treatment options.
Vonoprazan for H pylori infection (1 Apr 2020) [PDF, 40 KB]
Vonoprazan for H pylori infection PES (1 Apr 2020) [PDF, 34 KB]